Elevated serum IP-10 levels observed in type 1 diabetes.

Area of Science:

• Immunology
• Endocrinology
• Diabetology

Background:

• Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells, primarily mediated by T-cells.
• A reliable method to measure pancreatic beta-cell-specific T-cell function in type 1 diabetes is lacking.
• Interferon-inducible protein-10 (IP-10) is a chemokine associated with T-helper 1 (Th1) cell migration, relevant to Th1-mediated diseases like type 1 diabetes.

Purpose of the Study:

• To investigate serum IP-10 levels as a potential biomarker for T-cell activity in type 1 diabetes.
• To correlate IP-10 levels with autoantibody status and T-cell responses in patients with type 1 diabetes.

Main Methods:

• Serum samples from type 1 diabetes patients (classified as Ab+ or Ab- based on autoantibodies) and healthy controls were analyzed for IP-10 levels.
• Peripheral blood mononuclear cells were stimulated with GAD antigen, and intracellular cytokine staining was performed using flow cytometry to quantify GAD-reactive T-cells.
• Statistical analyses were used to compare IP-10 levels and correlate them with clinical and immunological parameters.

Main Results:

• Serum IP-10 levels were significantly higher in both Ab+ and Ab- type 1 diabetes groups compared to healthy subjects.
• Recent-onset Ab+ type 1 diabetes patients exhibited higher IP-10 levels than those with established disease.
• A significant positive correlation was observed between serum IP-10 levels and the frequency of GAD-reactive gamma-interferon-producing CD4+ T-cells in the Ab+ type 1 group.

Conclusions:

• Serum IP-10 measurement is a valuable tool for assessing T-cell activity in type 1 diabetes.
• IP-10 may serve as a biomarker reflecting the autoimmune process in type 1 diabetes, particularly in relation to GAD antigen-specific T-cell responses.